BRIGHT MINDS BIOSCIENCES INC (DRUG) Forecast, Price Target & Analyst Ratings
NASDAQ:DRUG • CA10919W4056
80 USD
-2.81 (-3.39%)
At close: Mar 3, 2026
80 USD
0 (0%)
After Hours: 3/3/2026, 8:06:14 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRIGHT MINDS BIOSCIENCES INC (DRUG).
Forecast Snapshot
Consensus Price Target
N/A
N/A
Next Earnings Forecast
Release DateMay 13, 2026
ChartMill Buy Consensus
85.71%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $80.00 to mean target of N/A, Based on 7 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
85.71%
DRUG was analyzed by 7 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about DRUG.
In the previous month the buy percentage consensus was at a similar level.
DRUG was analyzed by 7 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-02-17 | BTIG | Maintains | Buy -> Buy |
| 2026-01-07 | BTIG | Maintains | Buy -> Buy |
| 2026-01-06 | BTIG | Maintains | Buy -> Buy |
| 2026-01-02 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-12-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-08 | BTIG | Initiate | Buy |
| 2025-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-05-21 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-13 | TD Cowen | Initiate | Buy |
| 2025-05-07 | Chardan Capital | Initiate | Buy |
| 2025-02-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-23 | Piper Sandler | Initiate | Overweight |
| 2025-01-10 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-01-10 | HC Wainwright & Co. | Initiate | Buy |
| 2024-11-25 | Baird | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 13, 2026
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | ||
|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | ||||||||
| EBITDA YoY % growth | N/A | N/A | N/A | -14.967M | -7.294M 51.26% | -2.74M 62.43% | -13.825M -404.48% | |
| EBIT YoY % growth | -78.7K | -480.4K -510.42% | -8.805M -1,732.83% | -14.973M -70.05% | -7.367M 50.80% | -2.814M 61.80% | -13.902M -394.05% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
All data in CAD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in CAD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
BRIGHT MINDS BIOSCIENCES INC / DRUG Forecast FAQ
When does BRIGHT MINDS BIOSCIENCES INC (DRUG) report earnings?
BRIGHT MINDS BIOSCIENCES INC (DRUG) will report earnings on 2026-05-13.
What is the number of analysts for DRUG stock?
The number of analysts covering BRIGHT MINDS BIOSCIENCES INC (DRUG) is 7.